Complementary action. One tablet

Footnotes

• *
  Glyxambi® is indicated to improve glycaemic control when metformin and/or sulfonylurea and one of the mono-components of Glyxambi® do not provide adequate glycaemic control, or when already being treated with the free combination of empagliflozin and linagliptin.¹
• †
  Centre for Drug Evaluation and Research. Accessed from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206073Orig1s000Approv.pdf Accessed on: November 14, 2025.
• ‡
  Food and Drug Administration. FDA Approved drugs. Accessed from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206073s044lbl.pdf Accessed on: November 14, 2025.
• §
  Taken anytime, with or without food. Not recommended for use in patients with persistent estimated glomerular filtration rate <30 mL/min/1.73 m². Recommended dose is 5/10 mg, while the 5/25 mg is used in patients tolerating empagliflozin + linagliptin = (Glyxambi®) 5/10 mg.¹
• ||
  Empagliflozin + linagliptin (Glyxambi®) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. Empagliflozin + linagliptin (Glyxambi®) is not indicated for patients with type 1 diabetes mellitus.^1,4
• ¶
  Glyxambi® is not indicated for weight loss or blood pressure reduction.^1,4
• **
  Glyxambi® is a fixed-dose combination of empagliflozin and linagliptin. It has not been studied in a dedicated cardiovascular or renal outcomes trial.¹
• ††
  Caution should be advised when used with insulin and sulphonylureas which may increase the risk of hypoglycemia.¹

References

1. Glyxambi® Summary of Product Characteristics UAE; August 2025.

2. Frois C, Dea K, Ling D, et al. Poster presented at: Association for the Study of Diabetes Conference; September 15–19, 2014; Vienna, Austria.

3. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71-5.

4. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384-393.

5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

6. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.

7. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127.

8. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomised clinical trial. JAMA. 2019;321(1):69-79.

9. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomised clinical trial. JAMA. 2019;322(12):1155-1166.

10. Rosenstock J, Perkovic V, Alexander JH, et al. Rationale, design, and baseline characteristics of the cardiovascular safety and renal microvascular outcome study with linagliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17(1):39.

11. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the cardiovascular outcome trial of linagliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res. 2015;12(3):164-174.